Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- University of Heidelberg Medical Center
- Target Recruit Count
- 130
- Registration Number
- NCT05695508
- Locations
- 🇩🇪
Charité University Medicin Berlin, Berlin, Germany
🇩🇪Clinic Chemnitz gGmbH, Chemnitz, Germany
🇩🇪University Clinic Technical University Dresden, Dresden, Germany
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
- Conditions
- Newly Diagnosed Multiple Myeloma
- Interventions
- Other: autologous stem cell transplant
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- University Hopsital Schleswig Holstein Campus Lübeck
- Target Recruit Count
- 100
- Registration Number
- NCT05665140
- Locations
- 🇩🇪
Heloisklinikum Berlin Buch GmbH, Berlin, Germany
🇩🇪Klinikum Bielefeld - Onkologie, Hämatologie, Paliativmedizin, Bielefeld, Germany
🇩🇪Universitätsklinikum Münster, Münster, Germany
The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT05599880
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Guri-si, Korea, Republic of
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT05572515
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇧🇪CHR de la Citadelle, Liege, Belgium
🇧🇷Hospitais Integradaos da Gavea S/A - DF Star, Brasilia, Brazil
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Lymphoma, Mantle-Cell
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT05564052
- Locations
- 🇵🇱
Szpital Specjalistyczny im Jedrzeja Sniadeckiego w Nowym Saczu, Nowy Sacz, Poland
🇵🇱Specjalistyczny Szpital im dra Alfreda Sokolowskiego w Walbrzychu, Walbrzych, Poland
🇧🇷Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Conditions
- Plasma Cell Myeloma
- Interventions
- Other: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 510
- Registration Number
- NCT05561387
- Locations
- 🇺🇸
Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States
🇺🇸Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸Saint Anthony's Health, Alton, Illinois, United States
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
- Conditions
- Newly Diagnosed Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 480
- Registration Number
- NCT05558319
- Locations
- 🇪🇸
Hospital Principe de Asturias, Alcalá de Henares, Madrid, Spain
🇪🇸Hospital Germans Trias i Pujol (ICO BADALONA), Badalona, Spain
🇪🇸Clinica Universidad Navarra (CUN), Pamplona, Navarra, Spain
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 15
- Registration Number
- NCT05556616
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸Scripps Health, San Diego, California, United States
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 810
- Registration Number
- NCT05519085
- Locations
- 🇺🇸
Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
🇺🇸Sharp Memorial Hospital, San Diego, California, United States
🇺🇸Private Practice - Dr. James R. Berenson, West Hollywood, California, United States
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
- Conditions
- Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 42
- Registration Number
- NCT05514990
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Los Angeles County-USC Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.